ArticleCancers2021
HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Frequent detection of high-risk HPV types other than HPV 16/18 in a cohort of French women who claimed to have been vaccinated.Archives of virology · 2026Article
- International Collaborative Study on Human Papillomavirus Analytical Thresholds for Sensitivity and Specificity in Cervical Screening.Journal of medical virology · 2026Article
- Pathological changes of high-risk human papillomavirus-positive cervical lesions after surgery and analysis of risk factors for persistent positivity.American journal of translational research · 2026Article
- Human Papillomavirus Genotyping and Viral Load as a Predictor of Cervical Lesions: A Prospective Study.Journal of medical virology · 2025Article
- Analysis of HPV-16 viral load, integration status, and p16 expression in relation to EBV co-infection and cervical lesion severity.Scientific reports · 2025Article
- Viral and immune dynamics of genital human papillomavirus infections in young women with high temporal resolution.PLoS biology · 2025Observational
- Correlation of different HPV genotype viral loads and cervical lesions: A retrospective analysis of 1585 cases.Cancer cytopathology · 2025Article
- The Hallmarks of Cervical Cancer: Molecular Mechanisms Induced by Human Papillomavirus.Biology · 2024Review
- Analysis of factors affecting the accuracy of colposcopic diagnosis of cervical lesions: a retrospective cohort study.Frontiers in medicine · 2024Article
- Detection of cervical high-grade squamous intraepithelial lesions and assessing diagnostic performance of colposcopy among women with oncogenic HPV.BMC women's health · 2023Article
- Relative distribution of HPV genotypes in histological cervical samples and associated grade lesion in a women population over the last 16 years in Burgundy, France.Frontiers in medicine · 2023Article
- Correlation between human papillomavirus viral load and cervical lesions classification: A review of current research.Frontiers in medicine · 2023Review
- E7-Targeted Nanotherapeutics for Key HPV Afflicted Cervical Lesions by Employing CRISPR/Cas9 and Poly (Beta-Amino Ester).International journal of nanomedicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-risk HPV (hrHPV) testing has been implemented as a primary screening tool for cervical cancer in numerous countries. However, there is still a need for relevant triage strategies to manage hrHPV positive women to avoid excessive referral to colposcopy. The objective of this study was to assess, in women infected by hrHPV and presenting no or mild cytological abnormalities, HPV16 and HPV18 viral loads to predict the development of cervical high-grade lesion. Among 2102 women positive for hrHPV, 885 had no lesion or mild cytological abnormalities at baseline and had at least one follow-up (FU) visit. HPV16 and HPV18 prevalence was 25.9% and 8.4%, respectively. Of those women, 15% developed a high-grade lesion during the FU. An HPV16 viral load cut-off set at 3.2 log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.